Comparative Pharmacology
Head-to-head clinical analysis: ONGENTYS versus TASMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGENTYS versus TASMAR.
ONGENTYS vs TASMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ongentys (opicapone) is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). By inhibiting COMT, it decreases the metabolism of levodopa to 3-O-methyldopa, thereby increasing plasma levodopa levels and enhancing its bioavailability in the brain, leading to improved dopaminergic effects.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which increases the bioavailability of levodopa by reducing its peripheral metabolism.
50 mg orally once daily, taken at bedtime.
100 mg orally three times daily; maximum 200 mg three times daily.
None Documented
None Documented
The terminal elimination half-life of opicapone is approximately 1 to 2 hours at low doses, but at therapeutic doses (50 mg) it exhibits nonlinear pharmacokinetics with an effective half-life of about 12 to 16 hours due to tight binding to COMT enzyme, allowing once-daily dosing.
Terminal elimination half-life is 2–3 hours in healthy volunteers; clinically, this short half-life necessitates three-times-daily dosing to maintain COMT inhibition, though peripheral COMT activity recovers within 4–6 hours.
Following oral administration, approximately 30% of the dose is excreted in urine as unchanged opicapone, with an additional 10% as glucuronide conjugates. The remainder is eliminated via biliary/fecal routes, accounting for about 60% of the dose.
Primarily hepatic metabolism (glucuronidation and methylation), with approximately 40% of the dose excreted in urine as metabolites and <0.5% as unchanged drug; about 50% is eliminated in feces via biliary excretion.
Category C
Category C
COMT Inhibitor
COMT Inhibitor